JP2013523652A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013523652A5 JP2013523652A5 JP2013501501A JP2013501501A JP2013523652A5 JP 2013523652 A5 JP2013523652 A5 JP 2013523652A5 JP 2013501501 A JP2013501501 A JP 2013501501A JP 2013501501 A JP2013501501 A JP 2013501501A JP 2013523652 A5 JP2013523652 A5 JP 2013523652A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- compound
- alkyl
- group
- hydrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 20
- 229910052757 nitrogen Inorganic materials 0.000 claims 13
- 125000000217 alkyl group Chemical group 0.000 claims 12
- 229910052739 hydrogen Inorganic materials 0.000 claims 12
- 239000001257 hydrogen Substances 0.000 claims 12
- 125000005842 heteroatom Chemical group 0.000 claims 11
- 125000001072 heteroaryl group Chemical group 0.000 claims 9
- 229910052736 halogen Inorganic materials 0.000 claims 7
- 150000002367 halogens Chemical class 0.000 claims 7
- 150000002431 hydrogen Chemical group 0.000 claims 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 5
- 125000003545 alkoxy group Chemical group 0.000 claims 4
- 125000003118 aryl group Chemical group 0.000 claims 4
- 150000001204 N-oxides Chemical class 0.000 claims 3
- 125000000753 cycloalkyl group Chemical group 0.000 claims 3
- 125000000623 heterocyclic group Chemical group 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- 206010016654 Fibrosis Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 230000033115 angiogenesis Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000001419 dependent effect Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000004761 fibrosis Effects 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 206010020718 hyperplasia Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 208000037803 restenosis Diseases 0.000 claims 1
- 125000000547 substituted alkyl group Chemical group 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31722310P | 2010-03-24 | 2010-03-24 | |
| US61/317,223 | 2010-03-24 | ||
| PCT/US2011/029879 WO2011119894A2 (en) | 2010-03-24 | 2011-03-24 | Heterocyclic compounds useful for kinase inhibition |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016236174A Division JP6391126B2 (ja) | 2010-03-24 | 2016-12-05 | キナーゼ阻害に役立つ複素環式化合物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013523652A JP2013523652A (ja) | 2013-06-17 |
| JP2013523652A5 true JP2013523652A5 (enExample) | 2014-05-15 |
| JP6065183B2 JP6065183B2 (ja) | 2017-01-25 |
Family
ID=44673873
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013501501A Expired - Fee Related JP6065183B2 (ja) | 2010-03-24 | 2011-03-24 | キナーゼ阻害に役立つ複素環式化合物 |
| JP2016236174A Expired - Fee Related JP6391126B2 (ja) | 2010-03-24 | 2016-12-05 | キナーゼ阻害に役立つ複素環式化合物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016236174A Expired - Fee Related JP6391126B2 (ja) | 2010-03-24 | 2016-12-05 | キナーゼ阻害に役立つ複素環式化合物 |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US8957216B2 (enExample) |
| EP (1) | EP2550266B1 (enExample) |
| JP (2) | JP6065183B2 (enExample) |
| KR (2) | KR20180032686A (enExample) |
| CN (1) | CN102884060B (enExample) |
| AU (2) | AU2011232372B2 (enExample) |
| CA (1) | CA2794086A1 (enExample) |
| ES (1) | ES2677356T3 (enExample) |
| IL (1) | IL222068B (enExample) |
| MX (2) | MX345552B (enExample) |
| RU (2) | RU2640862C2 (enExample) |
| WO (1) | WO2011119894A2 (enExample) |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI491606B (zh) | 2009-07-13 | 2015-07-11 | Gilead Sciences Inc | 調節細胞凋亡信號之激酶的抑制劑 |
| WO2011097594A2 (en) * | 2010-02-08 | 2011-08-11 | Kinagen, Inc. | Therapeutic methods and compositions involving allosteric kinase inhibition |
| MX345552B (es) | 2010-03-24 | 2017-02-02 | Amitech Therapeutic Solutions Inc | Compuestos heterocíclicos útiles para inhibición de cinasa. |
| CN102985418B (zh) | 2010-07-02 | 2015-09-09 | 吉利德科学股份有限公司 | 凋亡信号调节激酶抑制剂 |
| EP2651417B1 (en) | 2010-12-16 | 2016-11-30 | Calchan Limited | Ask1 inhibiting pyrrolopyrimidine derivatives |
| US8754114B2 (en) | 2010-12-22 | 2014-06-17 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3 |
| US9408885B2 (en) | 2011-12-01 | 2016-08-09 | Vib Vzw | Combinations of therapeutic agents for treating melanoma |
| UY34573A (es) | 2012-01-27 | 2013-06-28 | Gilead Sciences Inc | Inhibidor de la quinasa que regula la señal de la apoptosis |
| RS61089B1 (sr) | 2012-06-13 | 2020-12-31 | Incyte Holdings Corp | Supstituisana triciklična jedinjenja kao inhibitori fgfr |
| WO2014026125A1 (en) | 2012-08-10 | 2014-02-13 | Incyte Corporation | Pyrazine derivatives as fgfr inhibitors |
| US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
| DK2986610T5 (en) | 2013-04-19 | 2018-12-10 | Incyte Holdings Corp | BICYCLIC HETEROCYCLES AS FGFR INHIBITORS |
| EP3134405B1 (en) * | 2014-04-25 | 2019-08-28 | Pfizer Inc | Heteroaromatic compounds and their use as dopamine d1 ligands |
| AP2016009512A0 (en) * | 2014-04-25 | 2016-10-31 | Pfizer | Heteroaromatic compounds and their use as dopamine d1 ligands |
| SG11201701723XA (en) | 2014-09-24 | 2017-04-27 | Gilead Sciences Inc | Methods of treating liver disease |
| US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| MA41252A (fr) | 2014-12-23 | 2017-10-31 | Gilead Sciences Inc | Formes solides d'un inhibiteur d'ask 1 |
| WO2016106384A1 (en) | 2014-12-23 | 2016-06-30 | Gilead Sciences, Inc. | Processes for preparing ask1 inhibitors |
| WO2016134294A1 (en) | 2015-02-20 | 2016-08-25 | Incyte Corporation | Bicyclic heterocycles as fgfr4 inhibitors |
| SG11201706287PA (en) | 2015-02-20 | 2017-09-28 | Incyte Corp | Bicyclic heterocycles as fgfr inhibitors |
| MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
| WO2016161952A1 (zh) * | 2015-04-07 | 2016-10-13 | 广东众生药业股份有限公司 | 酪氨酸激酶抑制剂及包含该酪氨酸激酶抑制剂的药物组合物 |
| JP7300394B2 (ja) | 2017-01-17 | 2023-06-29 | ヘパリジェニックス ゲーエムベーハー | 肝再生の促進又は肝細胞死の低減もしくは予防のためのプロテインキナーゼ阻害 |
| EP3579872A1 (en) | 2017-02-10 | 2019-12-18 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of cancers associated with activation of the mapk pathway |
| AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
| US11725185B2 (en) | 2017-12-28 | 2023-08-15 | University Of Houston System | Stem cell culture systems for columnar epithelial stem cells, and uses related thereto |
| CN108191781B (zh) * | 2018-01-08 | 2020-01-21 | 浙江大学 | 取代三氮唑类衍生物及其在制备抗肿瘤转移药物中的应用 |
| GB201801226D0 (en) | 2018-01-25 | 2018-03-14 | Redx Pharma Plc | Modulators of Rho-associated protein kinase |
| KR20210018264A (ko) | 2018-05-04 | 2021-02-17 | 인사이트 코포레이션 | Fgfr 억제제의 염 |
| WO2019213544A2 (en) | 2018-05-04 | 2019-11-07 | Incyte Corporation | Solid forms of an fgfr inhibitor and processes for preparing the same |
| CN108586439A (zh) * | 2018-06-03 | 2018-09-28 | 刘思良 | 一种Raf激酶抑制剂及其在癌症治疗中的应用 |
| CN108610336A (zh) * | 2018-06-03 | 2018-10-02 | 刘思良 | 一种重氮类衍生物及其在癌症治疗中的应用 |
| CN108864060A (zh) * | 2018-06-03 | 2018-11-23 | 刘思良 | 一种重氮类衍生物及其在癌症治疗中的应用 |
| US11628162B2 (en) | 2019-03-08 | 2023-04-18 | Incyte Corporation | Methods of treating cancer with an FGFR inhibitor |
| MX2021009863A (es) | 2019-03-21 | 2021-11-12 | Onxeo | Una molecula dbait en combinacion con inhibidor de quinasa para el tratamiento del cancer. |
| US12523663B2 (en) | 2019-06-04 | 2026-01-13 | Inserm (Institut National De La Santé Et De La Rescherche Médicale) | Use of CD9 as a biomarker and as a biotarget in glomerulonephritis or glomerulosclerosis |
| WO2021007269A1 (en) | 2019-07-09 | 2021-01-14 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| WO2021067374A1 (en) | 2019-10-01 | 2021-04-08 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| EP4045151A1 (en) | 2019-10-14 | 2022-08-24 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| US11566028B2 (en) | 2019-10-16 | 2023-01-31 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| WO2021089791A1 (en) | 2019-11-08 | 2021-05-14 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
| WO2021113479A1 (en) | 2019-12-04 | 2021-06-10 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| IL293001A (en) | 2019-12-04 | 2022-07-01 | Incyte Corp | Derivatives of fgfr repressors |
| US12012409B2 (en) | 2020-01-15 | 2024-06-18 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| WO2021155004A1 (en) * | 2020-01-30 | 2021-08-05 | The Regents Of The University Of California | Strad-binding agents and uses thereof |
| JP2024513575A (ja) | 2021-04-12 | 2024-03-26 | インサイト・コーポレイション | Ｆｇｆｒ阻害剤及びネクチン－４標的化剤を含む併用療法 |
| WO2022261160A1 (en) | 2021-06-09 | 2022-12-15 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| TW202313610A (zh) | 2021-06-09 | 2023-04-01 | 美商英塞特公司 | 作為ｆｇｆｒ抑制劑之三環雜環 |
| CN119173506A (zh) | 2022-05-19 | 2024-12-20 | 阿斯利康(瑞典)有限公司 | 用于治疗肝病的酰胺杂芳香族化合物 |
| WO2023222849A1 (en) * | 2022-05-19 | 2023-11-23 | Astrazeneca Ab | Amino heteroaromatic compounds useful in the treatment of liver diseases |
Family Cites Families (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| US3993073A (en) | 1969-04-01 | 1976-11-23 | Alza Corporation | Novel drug delivery device |
| US3598122A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| US3710795A (en) | 1970-09-29 | 1973-01-16 | Alza Corp | Drug-delivery device with stretched, rate-controlling membrane |
| US4069307A (en) | 1970-10-01 | 1978-01-17 | Alza Corporation | Drug-delivery device comprising certain polymeric materials for controlled release of drug |
| US3731683A (en) | 1971-06-04 | 1973-05-08 | Alza Corp | Bandage for the controlled metering of topical drugs to the skin |
| US3742951A (en) | 1971-08-09 | 1973-07-03 | Alza Corp | Bandage for controlled release of vasodilators |
| US3996934A (en) | 1971-08-09 | 1976-12-14 | Alza Corporation | Medical bandage |
| BE795384A (fr) | 1972-02-14 | 1973-08-13 | Ici Ltd | Pansements |
| US3921636A (en) | 1973-01-15 | 1975-11-25 | Alza Corp | Novel drug delivery device |
| US3993072A (en) | 1974-08-28 | 1976-11-23 | Alza Corporation | Microporous drug delivery device |
| US3972995A (en) | 1975-04-14 | 1976-08-03 | American Home Products Corporation | Dosage form |
| US4077407A (en) | 1975-11-24 | 1978-03-07 | Alza Corporation | Osmotic devices having composite walls |
| US4031894A (en) | 1975-12-08 | 1977-06-28 | Alza Corporation | Bandage for transdermally administering scopolamine to prevent nausea |
| US4031893A (en) | 1976-05-14 | 1977-06-28 | Survival Technology, Inc. | Hypodermic injection device having means for varying the medicament capacity thereof |
| US4060084A (en) | 1976-09-07 | 1977-11-29 | Alza Corporation | Method and therapeutic system for providing chemotherapy transdermally |
| US4201211A (en) | 1977-07-12 | 1980-05-06 | Alza Corporation | Therapeutic system for administering clonidine transdermally |
| JPS5562012A (en) | 1978-11-06 | 1980-05-10 | Teijin Ltd | Slow-releasing preparation |
| US4230105A (en) | 1978-11-13 | 1980-10-28 | Merck & Co., Inc. | Transdermal delivery of drugs |
| US4291015A (en) | 1979-08-14 | 1981-09-22 | Key Pharmaceuticals, Inc. | Polymeric diffusion matrix containing a vasodilator |
| US5116817A (en) | 1982-12-10 | 1992-05-26 | Syntex (U.S.A.) Inc. | LHRH preparations for intranasal administration |
| US4476116A (en) | 1982-12-10 | 1984-10-09 | Syntex (U.S.A.) Inc. | Polypeptides/chelating agent nasal compositions having enhanced peptide absorption |
| US5312325A (en) | 1987-05-28 | 1994-05-17 | Drug Delivery Systems Inc | Pulsating transdermal drug delivery system |
| US5633009A (en) | 1990-11-28 | 1997-05-27 | Sano Corporation | Transdermal administration of azapirones |
| US5695472A (en) | 1993-05-27 | 1997-12-09 | Washington Biotech Corporation | Modular automatic or manual emergency medicine injection system |
| US5358489A (en) | 1993-05-27 | 1994-10-25 | Washington Biotech Corporation | Reloadable automatic or manual emergency injection system |
| US5540664A (en) | 1993-05-27 | 1996-07-30 | Washington Biotech Corporation | Reloadable automatic or manual emergency injection system |
| AU3087195A (en) * | 1994-08-02 | 1996-03-04 | Nippon Soda Co., Ltd. | Oxazole derivative, process for producing the same, and herbicide |
| US5665378A (en) | 1994-09-30 | 1997-09-09 | Davis; Roosevelt | Transdermal therapeutic formulation |
| US6923983B2 (en) | 1996-02-19 | 2005-08-02 | Acrux Dds Pty Ltd | Transdermal delivery of hormones |
| US6929801B2 (en) | 1996-02-19 | 2005-08-16 | Acrux Dds Pty Ltd | Transdermal delivery of antiparkinson agents |
| US6391452B1 (en) | 1997-07-18 | 2002-05-21 | Bayer Corporation | Compositions for nasal drug delivery, methods of making same, and methods of removing residual solvent from pharmaceutical preparations |
| US5869090A (en) | 1998-01-20 | 1999-02-09 | Rosenbaum; Jerry | Transdermal delivery of dehydroepiandrosterone |
| US6946144B1 (en) | 1998-07-08 | 2005-09-20 | Oryxe | Transdermal delivery system |
| US7544189B2 (en) | 2000-10-10 | 2009-06-09 | Meridian Medical Technologies, Inc. | Needle and hub assembly for automatic injector |
| CA2463724A1 (en) * | 2001-10-16 | 2003-04-24 | Structural Bioinformatics Inc. | Organosulfur inhibitors of tyrosine phosphatases |
| US7189712B2 (en) * | 2002-10-10 | 2007-03-13 | Smithkline Beecham Corporation | 1,3-Oxazole compounds for the treatment of cancer |
| TWI335913B (en) * | 2002-11-15 | 2011-01-11 | Vertex Pharma | Diaminotriazoles useful as inhibitors of protein kinases |
| US20090048301A1 (en) | 2003-07-09 | 2009-02-19 | Imclone Systems Incorporated | Heterocyclic compounds and their use as anticancer agents |
| JP2008510814A (ja) * | 2004-08-23 | 2008-04-10 | ワイス | Ｐａｉ−１阻害剤としてのピロロ−ナフチル酸 |
| BRPI0514544A (pt) | 2004-08-23 | 2008-06-17 | Wyeth Corp | ácidos de oxazol-naftila como moduladores de inibidor tipo-1 de ativador de plasminogênio (pai-1) |
| EP1799656A4 (en) | 2004-08-25 | 2009-09-02 | Targegen Inc | HETEROCYCLIC COMPOUNDS AND METHODS OF USE |
| CN101044125A (zh) * | 2004-08-25 | 2007-09-26 | 塔尔基公司 | 杂环化合物和应用方法 |
| CA2593857A1 (en) * | 2005-02-01 | 2006-08-10 | Wyeth | Amino-pyridines as inhibitors of .beta.-secretase |
| JP5201817B2 (ja) * | 2005-10-28 | 2013-06-05 | 大塚製薬株式会社 | 医薬組成物 |
| US7868177B2 (en) * | 2006-02-24 | 2011-01-11 | Amgen Inc. | Multi-cyclic compounds and method of use |
| US7932390B2 (en) * | 2006-06-29 | 2011-04-26 | Hoffman-La Roche Inc. | Substituted thieno[3,2-C]pyridine carboxylic acid derivatives |
| CN101600712A (zh) * | 2007-01-29 | 2009-12-09 | 参天制药株式会社 | 具有血管新生抑制活性的新型噁二唑衍生物及噻二唑衍生物 |
| HUE028840T2 (en) | 2009-02-04 | 2017-01-30 | Otsuka Pharma Factory Inc | Phenylimidazole compounds |
| WO2011097594A2 (en) * | 2010-02-08 | 2011-08-11 | Kinagen, Inc. | Therapeutic methods and compositions involving allosteric kinase inhibition |
| MX345552B (es) | 2010-03-24 | 2017-02-02 | Amitech Therapeutic Solutions Inc | Compuestos heterocíclicos útiles para inhibición de cinasa. |
-
2011
- 2011-03-24 MX MX2016006136A patent/MX345552B/es unknown
- 2011-03-24 EP EP11760266.4A patent/EP2550266B1/en not_active Not-in-force
- 2011-03-24 JP JP2013501501A patent/JP6065183B2/ja not_active Expired - Fee Related
- 2011-03-24 KR KR1020187008081A patent/KR20180032686A/ko not_active Ceased
- 2011-03-24 WO PCT/US2011/029879 patent/WO2011119894A2/en not_active Ceased
- 2011-03-24 KR KR1020127027421A patent/KR101844088B1/ko not_active Expired - Fee Related
- 2011-03-24 RU RU2012144751A patent/RU2640862C2/ru active
- 2011-03-24 CA CA2794086A patent/CA2794086A1/en not_active Abandoned
- 2011-03-24 CN CN201180023503.5A patent/CN102884060B/zh not_active Expired - Fee Related
- 2011-03-24 MX MX2012010980A patent/MX339192B/es active IP Right Grant
- 2011-03-24 AU AU2011232372A patent/AU2011232372B2/en not_active Ceased
- 2011-03-24 RU RU2018100142A patent/RU2018100142A/ru unknown
- 2011-03-24 US US13/636,298 patent/US8957216B2/en active Active
- 2011-03-24 ES ES11760266.4T patent/ES2677356T3/es active Active
-
2012
- 2012-09-23 IL IL222068A patent/IL222068B/en not_active IP Right Cessation
-
2015
- 2015-02-12 US US14/620,527 patent/US9212151B2/en not_active Expired - Fee Related
- 2015-12-10 US US14/965,334 patent/US10214513B2/en active Active
-
2016
- 2016-09-23 AU AU2016231623A patent/AU2016231623B2/en not_active Ceased
- 2016-12-05 JP JP2016236174A patent/JP6391126B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013523652A5 (enExample) | ||
| RU2012144751A (ru) | Гетероциклические соединения, эффективные для ингибирования киназы | |
| JP2017537940A5 (enExample) | ||
| RU2477723C2 (ru) | Ингибиторы протеинкиназ (варианты), их применение для лечения онкологических заболеваний и фармацевтическая композиция на их основе | |
| JP2016503797A5 (enExample) | ||
| JP2009536620A5 (enExample) | ||
| RU2016119519A (ru) | Соединения гетероарила в качестве ингибиторов btk и их применение | |
| JP2015511638A5 (enExample) | ||
| JP2017528498A5 (enExample) | ||
| JP2014511892A5 (enExample) | ||
| HRP20171957T1 (hr) | Derivati 2-(2,4,5-supstituiranog-anilino) pirimidina kao modulatori egfr koji su korisni za liječenje raka | |
| CY1118340T1 (el) | Αναστολεις κινασης | |
| JP2016530283A5 (enExample) | ||
| JP2018511631A5 (enExample) | ||
| CY1118102T1 (el) | Αλατα διαμινιου φαινοθειαζινης και η χρηση αυτων | |
| JP2014508804A5 (enExample) | ||
| JP2018522866A5 (enExample) | ||
| CY1117719T1 (el) | Παραγωγα αμινοπυριμιδινης ως διαμορφωτες της lrrk2 | |
| JP2011506494A5 (enExample) | ||
| JP2016506387A5 (enExample) | ||
| JP2017507122A5 (enExample) | ||
| JP2014511891A5 (enExample) | ||
| RU2013108348A (ru) | Конденсированные гетероарилы и их применение | |
| JP2014500265A5 (enExample) | ||
| CY1117105T1 (el) | Ενωσεις πυριδαζινονης και χρηση τους ως αναστολεις του daao |